Repligen(RGEN) - 2025 Q4 - Annual Report
2026-02-26 21:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 41 Seyon Street, Bldg. 1, Suite 100 ...
Indivior PLC(INDV) - 2025 Q4 - Annual Report
2026-02-26 21:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37835 Indivior Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) State or other jurisdiction of incorporation or organization Delaware 41-2520873 (I.R ...
OUTFRONT Media(OUT) - 2025 Q4 - Annual Report
2026-02-26 21:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36367 OUTFRONT Media Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...
Apollo Investment(AINV) - 2025 Q4 - Annual Report
2026-02-26 21:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 814-00646 MIDCAP FINANCIAL INVESTMENT CORPORATION (Exact name of Registrant as specified in its charter) | Maryland | 52-2439556 | | --- | --- | | (State or other ...
MidCap Financial Investment (MFIC) - 2025 Q4 - Annual Report
2026-02-26 21:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 814-00646 MIDCAP FINANCIAL INVESTMENT CORPORATION (Exact name of Registrant as specified in its charter) | Maryland | 52-2439556 | | --- | --- | | (State or other ...
PACS Group, Inc.(PACS) - 2025 Q4 - Annual Results
2026-02-26 21:03
PACS Group, Inc. Reports Fiscal Year and Fourth Quarter 2025 Results Conference Call and Webcast Scheduled for Today, February 26, 2026, at 5:30 pm ET. SALT LAKE CITY, Utah, February 26, 2026 – PACS Group, Inc. (NYSE: PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the fiscal year and fourth quarter of 2025. Full Year 2025 Financial Highlights Fourth Quarter 2025 Financial Highli ...
Xenon(XENE) - 2025 Q4 - Annual Results
2026-02-26 21:03
Exhibit 99.1 Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update VANCOUVER, British Columbia and BOSTON, MA, Feb 26, 2026 – Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update. "2025 marked a ...
Integra LifeSciences(IART) - 2025 Q4 - Annual Report
2026-02-26 21:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR OTHER ...
Intuit(INTU) - 2026 Q2 - Quarterly Results
2026-02-26 21:02
Exhibit 99.01 Contacts: Investors Media Anne-Sophie Seigneurbieux Kali Fry Intuit Inc. Intuit Inc. 650-944-5655 650-944-3036 anne-sophie_seigneurbieux@intuit.com kali_fry@intuit.com Intuit Reports Strong Second-Quarter Results and Reiterates Full-Year Guidance Global Business Solutions Online Ecosystem Revenue Grew 21 percent; Consumer Revenue Grew 15 percent MOUNTAIN VIEW, Calif. - February 26, 2026 - Intuit Inc. (Nasdaq: INTU), the global financial technology platform that makes Intuit TurboTax, Credit Ka ...
Montrose Environmental(MEG) - 2025 Q4 - Annual Report
2026-02-26 21:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39394 Montrose Environmental Group, Inc. (Exact name of Registrant as specified in its Charter) Delaware 46-4195044 (State or other j ...